论文部分内容阅读
目的观察缬沙坦胶囊联合黄葵胶囊治疗糖尿病肾病(DN)的疗效。方法将80例DN患者随机分为治疗组和对照组各40例。治疗组在传统治疗基础上加用缬沙坦胶囊和黄葵胶囊治疗。对照组在传统治疗基础上加用缬沙坦胶囊治疗。比较2组临床疗效和治疗前、治疗后4、8、20周尿白蛋白量及不良反应发生情况。结果治疗组总有效率为92.5%高于对照组的77.5%,差异有统计学意义(P<0.05)。治疗前,2组患者尿白蛋白水平比较差异无统计学意义(P>0.05)。治疗第4、8、20周2组患者尿白蛋白水平均降低,且治疗组低于对照组,差异均有统计学意义(P<0.05)。2组不良反应发生发生率比较差异无统计学意义(P>0.05)。结论缬沙坦胶囊联合黄葵胶囊治疗DN可有效提高临床疗效,缩短治疗时间。
Objective To observe the curative effect of valsartan capsule and huang kui capsule on diabetic nephropathy (DN). Methods 80 patients with DN were randomly divided into treatment group and control group, 40 cases each. Treatment group based on the traditional treatment plus valsartan capsules and Huang Kui capsule treatment. The control group in the traditional treatment plus valsartan capsule treatment. The clinical efficacy and the levels of urinary albumin and adverse reactions at 4, 8 and 20 weeks after treatment were compared between the two groups. Results The total effective rate of the treatment group was 92.5% higher than that of the control group (77.5%), the difference was statistically significant (P <0.05). Before treatment, urinary albumin levels in two groups showed no significant difference (P> 0.05). The urinary albumin levels in the two groups were decreased on the 4th, 8th and 20th weeks after treatment, and the treatment group was lower than the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the two groups showed no significant difference (P> 0.05). Conclusion Valsartan capsules combined with Huang Kui capsule treatment of DN can effectively improve the clinical efficacy and shorten the treatment time.